Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials Network
Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials Network
批准号:
8088185
负责人:
Peter B. Gilbert
金额:
$871.81万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-06-29 至 2013-05-31
关键词:
AIDS preventionAIDS/HIV problemAcquired Immunodeficiency SyndromeAdjuvantAdolescentAdultAgeAntibodiesAntigensBiological AssayCase Report FormCharacteristicsClinicalClinical TrialsClinical Trials DesignClinical Trials NetworkCollectionCombined VaccinesCommon Data ElementCommunitiesCommunity Health EducationConduct Clinical TrialsCoordination and CollaborationDataData CollectionData SetDevelopmentDisease ProgressionDoseEffectivenessEnrollmentEpidemicEvaluationFundingGeneticGenital systemGeographic LocationsGoalsGrantGuidelinesHIVHIV InfectionsHIV Vaccine Trials NetworkHIV vaccineHIV-1Home environmentHumanImmune responseImmunityImmunology procedureIndividualInfectionInternationalLaboratoriesLaboratory StudyLeadershipLicensureLymphoid TissueMeasurementMediatingMethodologyMissionMonitorMucosal Immune ResponsesMucosal ImmunityNatural ImmunityPeripheral Blood Mononuclear CellPersonsPhasePhase II Clinical TrialsPlayPopulationPoxviridaePreventionPrevention ResearchPreventiveProcessProtocols documentationPublicationsQualifyingRandomizedRegimenReportingResearchRetrievalRiskRisk BehaviorsRoleRouteSafetyScheduleSecuritySeriesSiteSocial CharacteristicsStructureSurfaceSystemT-LymphocyteTestingTrainingUnited States National Institutes of HealthVaccinationVaccine ResearchVaccinesViralViremiaWomanantiretroviral therapycostcost effectivenessdata managementdefective adenoviral vectordesignefficacy evaluationefficacy trialexperiencefallshead-to-head comparisonhigh riskimmunogenicimmunogenicityimprovedmennoveloperationplasmid DNAprogramspublic health prioritiesresponsestandardize guidelinesstatistical centertransmission processvaccine candidatevaccine effectivenessvaccine efficacyvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This application to continue as the Statistical and Data Management Center (SDMC) for the HIV Vaccine
Trials Network (HVTN) is one of three applications comprising the Leadership Group of the HVTN. The
HVTN scientific agenda focuses exclusively on RFA priority number 1: 'Vaccine Researchand
Development." This application describes howthe Statistical Center for HIV/AIDS Research& Prevention
(SCHARP) will achieve the aims of the RFAto (1) provide statistical leadership for the design, conduct,
analysis and publication of Network clinical trials/studies; (2) provide central data management capability
that includes randomization, data set and case report form design, central storage, security, processing and
retrieval of study results; (3) provide data management and protocol training throughout the Network; (4)
provide data-focused clinical trials implementation, and operation; and (5) contribute to cross-Network
efforts in developing common data elements and data interfaces.
SCHARP has extensive experience in the design, conduct and analysis of global HIV vaccine and
prevention studies. Thus, the systems we propose to use for data collection, managment, monitoring, and
analysis are all well tested and in accordance with ICH guidelines. SCHARP statisticians will also develop
and deploy novel statistical methodologies to increase the efficiency and rigor of the proposed program of
HlV vaccine trials.
The HIV/AIDS epidemic continues to expand in almost all regions of the world, with approximately 4.8
million new infections in 2003 (UNAIDS 2004 Report on the Global AIDS Epidemic). Finding a safe, effective
vaccine that will protect persons against infection and/or disease progression is an international public-
health priority. Only through clinical trials held to the highest scientific and regulatory standards willthis goal
be achieved.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CoVPN Cross-Protocol Analyses
-
批准号:10570780
-
项目类别:
-
资助金额:$133.49万
-
财政年份:2022
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection
-
批准号:10581432
-
项目类别:
-
资助金额:$81.85万
-
财政年份:2022
-
负责人:Peter B. Gilbert
-
依托单位:
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals
-
批准号:10570787
-
项目类别:
-
资助金额:$101.18万
-
财政年份:2022
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3006: A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine
-
批准号:10375264
-
项目类别:
-
资助金额:$203.47万
-
财政年份:2021
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN Cross-Protocol Analyses
-
批准号:10322571
-
项目类别:
-
资助金额:$58.96万
-
财政年份:2021
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC
-
批准号:10319288
-
项目类别:
-
资助金额:$67.35万
-
财政年份:2021
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC
-
批准号:10320660
-
项目类别:
-
资助金额:$1832.23万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa
-
批准号:10609096
-
项目类别:
-
资助金额:$33.34万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN Cross-Protocol Analyses
-
批准号:10247368
-
项目类别:
-
资助金额:$136.73万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine SDMC
-
批准号:10217912
-
项目类别:
-
资助金额:$141.43万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals
-
批准号:10166307
-
项目类别:
-
资助金额:$40.16万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa
-
批准号:10378762
-
项目类别:
-
资助金额:$33.64万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
Statistical Methods in HIV Vaccine Efficacy Trials
-
批准号:9251714
-
项目类别:
-
资助金额:$36.88万
-
财政年份:2015
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3004 A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a SARS-CoV-2 Spike Protein Nanoparticle Vaccine in Adults
-
批准号:10581423
-
项目类别:
-
资助金额:$23.49万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN Cross-Protocol Analyses
-
批准号:10581848
-
项目类别:
-
资助金额:$184.68万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
-
批准号:10582009
-
项目类别:
-
资助金额:$1484.46万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3002 - A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study in Adults to Determine the safety, Efficacy, and Immunogenicity of AZD1222 for Prevention of Covid-19
-
批准号:10581359
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC
-
批准号:10570788
-
项目类别:
-
资助金额:$47.79万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
SDMC: HIV Vaccine Trials Network
-
批准号:8782602
-
项目类别:
-
资助金额:$1324.18万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals
-
批准号:10582056
-
项目类别:
-
资助金额:$29.37万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位: